Table 3 Breast cancer risk after cohort entry in distinct autoantibody strata, compared to the general population#
From: Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection
Antibody | Sample size | No. obs. | No. exp. | SLE cohort SIR (95% CI) | p value | AA* SIR (95% CI) | AA p value | Non-AA^ SIR (95% CI) | Non-AA p value |
|---|---|---|---|---|---|---|---|---|---|
All | 2431 | 22 | 34.9 | 0.63 (0.39–0.95) | 0.027 | 1.13 (0.65–1.84) | 0.69 | 0.29 (0.11–0.63) | < 0.001 |
dsDNA | 1503 | 12 | 21.7 | 0.55 (0.29–0.96) | 0.035 | 0.97 (0.44–1.84) | 0.99 | 0.24 (0.05–0.71) | 0.003 |
RNP | 709 | 9 | 7.3 | 1.24 (0.56–2.34) | 0.62 | 1.78 (0.77–3.50) | 0.17 | 0.36 (0.01–2.00) | 0.47 |
Sm | 507 | 2 | 4.9 | 0.41 (0.05–1.47) | 0.27 | 0.34 (0.01–1.90) | 0.42 | 0.51 (0.01–2.83) | 0.83 |
Ro | 756 | 4 | 10.2 | 0.39 (0.11–1.01) | 0.053 | 0.23 (0.01–1.26) | 0.13 | 0.52 (0.11–1.52) | 0.35 |
La | 313 | 0 | 4.7 | 0.00 (0.00–0.78) | 0.018 | 0.00 (0.00–2.28) | 0.40 | 0.00 (0.00–1.19) | 0.09 |
LAC | 615 | 4 | 11 | 0.37 (0.10–0.94) | 0.031 | 0.92 (0.25–2.36) | 0.99 | 0.00 (0.00–0.56) | 0.003 |
ACL | 1118 | 14 | 19.9 | 0.70 (0.38–1.18) | 0.21 | 1.35 (0.67–2.42) | 0.40 | 0.25 (0.05–0.74) | 0.005 |
Beta2GP1 | 446 | 4 | 9 | 0.44 (0.12–1.13) | 0.11 | 0.60 (0.07–2.17) | 0.71 | 0.35 (0.04–1.27) | 0.15 |